Anti-il-23 antibodies

Abstract

The present invention relates to anti-IL-23p19 binding compounds, in particular new humanized anti-IL-23p19 antibodies, pharmaceutical compositions and therapeutic and diagnostic methods and compositions for using the same.

1 . (canceled) 
     
     
         2 . (canceled) 
     
     
         3 . (canceled) 
     
     
         4 . (canceled) 
     
     
         5 . (canceled) 
     
     
         6 . (canceled) 
     
     
         7 . (canceled) 
     
     
         8 . (canceled) 
     
     
         9 . (canceled) 
     
     
         10 . A method for treating a subject having an IL-23-associated disorder comprising administering to the subject a pharmaceutical composition comprising (a) an anti-IL23p19 antibody, (b) a detergent, and (c) a tonicity agent, wherein the anti-IL23p19 antibody comprises a light chain amino acid sequence shown as SEQ ID NO:174 and a heavy chain amino acid sequence shown as SEQ ID NO:176, wherein the pharmaceutical composition has a pH in the range of 5.5 to 6.5, and wherein the formulation optionally comprises a buffer.
 according to  claim 5 , wherein said antibody binds to human IL-23.   
     
     
         11 . A method for treating an inflammatory disease, an autoimmune disease, a respiratory disease, a metabolic disorder or cancer comprising administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising (a) an anti-IL23p19 antibody, (b) a detergent, and (c) a tonicity agent, wherein the anti-IL23p19 antibody comprises a light chain amino acid sequence shown as SEQ ID NO:174 and a heavy chain amino acid sequence shown as SEQ ID NO:176, wherein the pharmaceutical composition has a pH in the range of 5.5 to 6.5, and wherein the formulation optionally comprises a buffer. 
     
     
         12 . The method according to  claim 11 , wherein the disease is psoriasis, inflammatory bowel disease, psoriatic arthritis, multiple sclerosis, rheumatoid arthritis, or spondyloarthritis. 
     
     
         13 . The method according to  claim 11 , wherein the disease is plaque psoriasis, chronic plaque psoriasis or moderate to severe chronic plaque psoriasis. 
     
     
         14 . The method according to  claim 11 , wherein the disease is palmar pustular psoriasis, guttate psoriasis, inverse psoriasis, pustular psoriasis or erythodermic psoriasis. 
     
     
         15 . The method according to  claim 11 , wherein the disease is Crohn's disease or ulcerative colitis. 
     
     
         16 . The method according to  claim 11 , wherein the disease is ankylosing spondylitis, non-radiographic axial spondyloarthritis or peripheral spondyloarthritis. 
     
     
         17 . The method according to  claim 11 , wherein the disease is discoid lupus, malaria, malignant melanoma, aplastic anaemia, Huntington's Disease, palmoplantar pustulosis, IgA nephritis, ANCA-Associated Vasculitis, scleritis or sepsis. 
     
     
         18 . A method for treating a disease comprising administering to a subject in need thereof an effective amount of an anti-IL-23p19 antibody or antigen-binding fragment thereof and a pharmaceutically acceptable carrier, wherein the antibody or antigen-binding fragment thereof comprises:
 a) a light chain variable region comprising the amino acid sequence of SEQ ID NO:19 (CDR1-L); the amino acid sequence of SEQ ID NO:20 (CDR2-L); and the amino acid sequence of SEQ ID NO:21 (CDR3-L); and   b) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 63, 66, 67 or 68 (CDR1-H); the amino acid sequence of SEQ ID NO:64 (CDR2-H); and the amino acid sequence of SEQ ID NO:65 (CDR3-H),   
       wherein the disease is:
 i) plaque psoriasis, chronic plaque psoriasis or moderate to severe chronic plaque psoriasis; or 
 ii) palmar pustular psoriasis, guttate psoriasis, inverse psoriasis, pustular psoriasis or erythodermic psoriasis; or 
 iii) non-radiographic axial spondyloarthritis or peripheral spondyloarthritis; or 
 iv) discoid lupus, malaria, malignant melanoma, aplastic anaemia, Huntington's Disease, palmoplantar pustulosis, IgA nephritis, ANCA-Associated Vasculitis, scleritis or sepsis. 
 
     
     
         19 . The method according to  claim 18 , wherein said antibody or antigen-binding fragment thereof comprises a light chain variable region comprising the amino acid sequence of any one of SEQ ID NO:158, 160, 162 or 164; and a heavy chain variable region comprising the amino acid sequence any one of SEQ ID NO:166, 168, 170 or 172. 
     
     
         20 . The method according to  claim 18 , wherein said antibody or antigen-binding fragment thereof comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO:160 and a heavy chain variable region comprising the amino acid sequence SEQ ID NO:166. 
     
     
         21 . The method according to  claim 18 , wherein said antibody or antigen-binding fragment thereof comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO:160 and a heavy chain variable region comprising the amino acid sequence SEQ ID NO:168. 
     
     
         22 . The method according to  claim 18 , wherein said antibody or antigen-binding fragment thereof comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO:158 and a heavy chain variable region comprising the amino acid sequence SEQ ID NO:166. 
     
     
         23 . The method according to  claim 18 , wherein said antibody or antigen-binding fragment thereof comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO:158 and a heavy chain variable region comprising the amino acid sequence SEQ ID NO:168. 
     
     
         24 . The method according to  claim 18 , wherein said antibody comprises a light chain comprising the amino acid sequence of SEQ ID NO:174 or 180 and a heavy chain comprising the amino acid sequence of SEQ ID NO:176 or 178. 
     
     
         25 . The method according to  claim 18 , wherein said antibody comprises a light chain comprising the amino acid sequence of SEQ ID NO:174 and a heavy chain comprising the amino acid sequence of SEQ ID NO:176. 
     
     
         26 . The method according to  claim 18 , wherein said antibody comprises a light chain comprising the amino acid sequence of SEQ ID NO:174 and a heavy chain comprising the amino acid sequence of SEQ ID NO:178. 
     
     
         27 . The method according to  claim 18 , wherein said antibody comprises a light chain comprising the amino acid sequence of SEQ ID NO:180 and a heavy chain comprising the amino acid sequence of SEQ ID NO:176. 
     
     
         28 . The method according to  claim 18 , wherein said antibody comprises a light chain comprising the amino acid sequence of SEQ ID NO: 180 and a heavy chain comprising the amino acid sequence of SEQ ID NO: 178.